ArticleBiochemistry and biophysics reports2025
Prognostic value and immune infiltration analysis of a novel lactylation-related gene signature in endometrial cancer.
Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Research progress on protein lactylation in female reproductive disease: molecular mechanisms, functions, and therapeutic implications.Frontiers in pharmacology · 2026Review
- The enzymatic mechanisms of lactylation and its role in gynecological diseases: a comprehensive review.Frontiers in immunology · 2026Review
- Decoding protein lactylation in the pathogenesis and progression of gynecological cancer.American journal of cancer research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lactylation has been implicated in tumor growth, proliferation, and metastasis; however, its precise relationship with cancer remains poorly understood. This study aims to elucidate the role of lactylation-related genes (LRGs) in the development of endometrial cancer (EC). Methods: We utilized data from The Cancer Genome Atlas (TCGA) database to analyze the expression and mutation patterns of LRGs in EC. Univariate Cox regression analysis and Lasso-Cox regression analysis were employed to identify prognosis-related genes and construct a risk model. EC samples were stratified into high-risk and low-risk groups based on the risk values derived from the model. These groups were validated using both training and validation cohorts. Additionally, we assessed differences in the immune microenvironment, tumor mutation burden (TMB), and drug response between the high-risk and low-risk groups. Results: Differentially expressed genes (DEGs) between EC and control samples were identified, and their intersection with LRGs yielded differentially expressed lactylation-related genes (DLRGs). A total of six prognostic DLRGs (PFKM, H3C1, SIRT3, VIM, WAS, and LSP1) were selected and used to construct an EC risk model. Significant differences in prognosis, immune microenvironment, TMB, and drug sensitivity were observed between the high-expression and low-expression groups. Conclusion: LRGs play a significant role in endometrial cancer by influencing cell growth, the immune microenvironment, and drug response. The six DLRGs included in the risk model may serve as potential prognostic markers and therapeutic targets for EC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.